论文部分内容阅读
应用MTT法检测了靶向性药物索拉非尼(Sorafenib)分别与阿霉素(ADM)、氟尿嘧啶(5-FU)、顺铂(DDP)和紫杉醇(PTX)等4种化疗药物按照不同给药序贯联合作用对肝癌细胞Bel-7402增殖的影响。结果表明,索拉非尼与4种化疗药物联用对Bel-7402细胞增殖的抑制作用效果均要好于单独用药,对细胞的IC_(50)明显低于单独用药。联合用药效果受到给药序贯的影响,索拉非尼先于化疗药物给药,CI值(除与紫杉醇联用)均大于1,表现为拮抗效应;索拉非尼后于化疗药物给药,CI值均小于1,表现为明显的协同效应。研究结果可供肝癌临床治疗参考,有助于临床降低用药剂量,减轻药物毒副作用。
MTT assay was used to detect the effect of targeted chemotherapy drug Sorafenib on ADM, 5-fluorouracil (5-FU), cisplatin (DDP) and paclitaxel (PTX) Effect of sequential combination of drugs on proliferation of hepatocellular carcinoma Bel-7402 cells. The results showed that sorafenib combined with 4 chemotherapeutic agents inhibited the proliferation of Bel-7402 cells better than single drug alone, and the IC 50 of the cells was significantly lower than that of the single drug alone. The effect of combination therapy was influenced by the sequential administration. Sorafenib was administered prior to chemotherapeutic drugs. The CI value (except for combination with paclitaxel) was greater than 1, which showed an antagonistic effect. Sorafenib was administered after chemotherapy , CI values are less than 1, showing a significant synergistic effect. The results for clinical treatment of liver cancer reference, help to reduce the dose of clinical and reduce drug side effects.